Products & Services
Exiqon's products and services are used by researchers in academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of disease. Taking advantage of our proprietary LNA™ technology, our product lines offer superior specificity and sensitivity for analysis of microRNA, mRNA and long non-coding RNA. Exiqon's products and services encompass the entire workflow from sample preparation to expression analysis (Sequencing, Array and qPCR), detection and functional analysis both in vitro and in vivo. Exiqon Services offers expertise in RNA Next Generation Sequencing, microRNA profiling and biomarker discovery from clinical samples.
By joining forces with QIAGEN, our products and services are now complemented by QIAGEN's global reach and powerful Sample to Insight® solutions. We continue to support your research with the dedication and expertise that you have come to expect from us.
Exiqon A/S was founded on 1 November 1995 and became operational in the spring of 1996. At the end of 1997, Exiqon secured the exclusive rights to the LNA™ (Locked Nucleic Acid) technology from the Danish inventors of the technology. Exiqon developed the LNA™ technology, including procedures for large-scale manufacturing and a large number of applications for the LNA™ technology, which have all been patented.
In 1999, Cureon A/S was founded as a subsidiary of Exiqon for the purpose of exploiting the therapeutic potential of the LNA™ technology. Cureon A/S later merged with Panteco A/S, forming the company Santaris Pharma A/S. Exiqon has since sold its stake in Santaris Pharma A/S. Santaris Pharma A/S was acquired by F. Hoffmann-La Roche AG in 2014. Exiqon has retained all rights to the LNA™ technology, except for therapeutic applications.
In 2003, Exiqon developed and implemented the product oriented strategy for its Life Sciences division. The first research product, Universal ProbeLibrary™, was launched in the spring of 2004. In 2005, Exiqon formed a strategic alliance with Roche Diagnostics for selling the Universal ProbeLibrary™.
In 2006, Exiqon established a subsidiary in the United States and a US sales organization.
In June 2016, Exiqon was acquired by QIAGEN
, bringing Exiqon's unique products and services into the QIAGEN portfolio.
In October 2017, Exiqon and QIAGEN officially joined forces
when Exiqon products and services became fully integrated with QIAGEN, and available for purchase only through QIAGEN